6 results on '"Kugbe Y"'
Search Results
2. Association between confirmed congenital Zika infection at birth and outcomes up to 3 years of life
- Author
-
Hcini, N., Kugbe, Y., Rafalimanana, ZHL, Lambert, V., Mathieu, M., Carles, G., Baud, D., Panchaud, A., and Pomar, L.
- Subjects
Adolescent ,Adult ,Child Development ,Child, Preschool ,Female ,French Guiana/epidemiology ,Humans ,Infant ,Infant, Newborn ,Male ,Maternal Age ,Nervous System Malformations/epidemiology ,Nervous System Malformations/etiology ,Pregnancy ,Pregnancy Complications, Infectious/diagnosis ,Pregnancy Complications, Infectious/virology ,Prenatal Exposure Delayed Effects/epidemiology ,Prenatal Exposure Delayed Effects/etiology ,Risk Assessment/statistics & numerical data ,Young Adult ,Zika Virus/isolation & purification ,Zika Virus Infection/complications ,Zika Virus Infection/congenital ,Zika Virus Infection/diagnosis ,Zika Virus Infection/virology - Abstract
Little is known about the long-term neurological development of children diagnosed with congenital Zika infection at birth. Here, we report the imaging and clinical outcomes up to three years of life of a cohort of 129 children exposed to Zika virus in utero. Eighteen of them (14%) had a laboratory confirmed congenital Zika infection at birth. Infected neonates have a higher risk of adverse neonatal and early infantile outcomes (death, structural brain anomalies or neurologic symptoms) than those who tested negative: 8/18 (44%) vs 4/111 (4%), aRR 10.1 [3.5-29.0]. Neurological impairment, neurosensory alterations or delays in motor acquisition are more common in infants with a congenital Zika infection at birth: 6/15 (40%) vs 5/96 (5%), aRR 6.7 [2.2-20.0]. Finally, infected children also have an increased risk of subspecialty referral for suspected neurodevelopmental delay by three years of life: 7/11 (64%) vs 7/51 (14%), aRR 4.4 [1.9-10.1]. Infected infants without structural brain anomalies also appear to have an increased risk, although to a lesser extent, of neurological abnormalities. It seems paramount to offer systematic testing for congenital ZIKV infection in cases of in utero exposure and adapt counseling based on these results.
- Published
- 2021
3. VP23.05: Prenatal and neonatal factors associated with a higher risk of abnormal development in children exposed to Zika virus in utero
- Author
-
Hcini, N., primary, Kugbe, Y., additional, Rafalimanana, Z., additional, Lambert, V., additional, Carles, G., additional, and Pomar, L., additional
- Published
- 2020
- Full Text
- View/download PDF
4. Association between confirmed congenital Zika infection at birth and outcomes up to 3 years of life.
- Author
-
Hcini N, Kugbe Y, Rafalimanana ZHL, Lambert V, Mathieu M, Carles G, Baud D, Panchaud A, and Pomar L
- Subjects
- Adolescent, Adult, Child, Preschool, Female, French Guiana epidemiology, Humans, Infant, Infant, Newborn, Male, Maternal Age, Nervous System Malformations etiology, Pregnancy, Pregnancy Complications, Infectious diagnosis, Prenatal Exposure Delayed Effects etiology, Risk Assessment statistics & numerical data, Young Adult, Zika Virus isolation & purification, Zika Virus Infection congenital, Zika Virus Infection diagnosis, Zika Virus Infection virology, Child Development, Nervous System Malformations epidemiology, Pregnancy Complications, Infectious virology, Prenatal Exposure Delayed Effects epidemiology, Zika Virus Infection complications
- Abstract
Little is known about the long-term neurological development of children diagnosed with congenital Zika infection at birth. Here, we report the imaging and clinical outcomes up to three years of life of a cohort of 129 children exposed to Zika virus in utero. Eighteen of them (14%) had a laboratory confirmed congenital Zika infection at birth. Infected neonates have a higher risk of adverse neonatal and early infantile outcomes (death, structural brain anomalies or neurologic symptoms) than those who tested negative: 8/18 (44%) vs 4/111 (4%), aRR 10.1 [3.5-29.0]. Neurological impairment, neurosensory alterations or delays in motor acquisition are more common in infants with a congenital Zika infection at birth: 6/15 (40%) vs 5/96 (5%), aRR 6.7 [2.2-20.0]. Finally, infected children also have an increased risk of subspecialty referral for suspected neurodevelopmental delay by three years of life: 7/11 (64%) vs 7/51 (14%), aRR 4.4 [1.9-10.1]. Infected infants without structural brain anomalies also appear to have an increased risk, although to a lesser extent, of neurological abnormalities. It seems paramount to offer systematic testing for congenital ZIKV infection in cases of in utero exposure and adapt counseling based on these results.
- Published
- 2021
- Full Text
- View/download PDF
5. Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research.
- Author
-
Gouyon B, Martin-Mons S, Iacobelli S, Razafimahefa H, Kermorvant-Duchemin E, Brat R, Caeymaex L, Couringa Y, Alexandre C, Lafon C, Ramful D, Bonsante F, Binson G, Flamein F, Moussy-Durandy A, Di Maio M, Mazeiras G, Girard O, Desbruyeres C, Mourdie J, Escourrou G, Flechelles O, Abasse S, Rosenthal JM, Pages AS, Dorsi M, Karaoui L, ElGellab A, Le Bail Dantec F, Yangui MA, Norbert K, Kugbe Y, Lorrain S, Pignolet A, Garnier EM, Lapillonne A, Mitanchez D, Jacqz-Aigrain E, and Gouyon JB
- Subjects
- Databases, Factual, Female, Gestational Age, Humans, Infant, Newborn, Infant, Premature, Male, Polypharmacy, Practice Patterns, Physicians' statistics & numerical data, Retrospective Studies, Drug Prescriptions statistics & numerical data, Environmental Exposure statistics & numerical data, Patients' Rooms statistics & numerical data, Prescription Drugs adverse effects
- Abstract
Objectives: The primary objective of this study is to determine the current level of patient medication exposure in Level 3 Neonatal Wards (L3NW). The secondary objective is to evaluate in the first month of life the rate of medication prescription not cited in the Summary of Product Characteristics (SmPC). A database containing all the medication prescriptions is collected as part of a prescription benchmarking program in the L3NW., Material and Methods: The research is a two-year observational cohort study (2017-2018) with retrospective analysis of medications prescribed in 29 French L3NW. Seventeen L3NW are present since the beginning of the study and 12 have been progressively included. All neonatal units used the same computerized system of prescription, and all prescription data were completely de-identified within each hospital before being stored in a common data warehouse., Results: The study population includes 27,382 newborns. Two hundred and sixty-one different medications (International Nonproprietary Names, INN) were prescribed. Twelve INN (including paracetamol) were prescribed for at least 10% of patients, 55 for less than 10% but at least 1% and 194 to less than 1%. The lowest gestational ages (GA) were exposed to the greatest number of medications (18.0 below 28 weeks of gestation (WG) to 4.1 above 36 WG) (p<0.0001). In addition, 69.2% of the 351 different combinations of an medication INN and a route of administration have no indication for the first month of life according to the French SmPC. Ninety-five percent of premature infants with GA less than 32 weeks received at least one medication not cited in SmPC., Conclusion: Neonates remain therapeutic orphans. The consequences of polypharmacy in L3NW should be quickly assessed, especially in the most immature infants., Competing Interests: Dr Beatrice Gouyon (1st author) was in charge of the B-PEN program (Benchmarking of Prescription in Neonatology) in the research center (CEPOI) from 2012 to 2016. Her employer was the University Hospital of La Reunion. Then Dr B. Gouyon left the CEPOI to take the lead of a new start-up (LogipremF comp.) responsible for the development of the prescription software Logipren and its implementation in the NICUs of the B-PEN network. This change of affiliation has been contracted with the University Hospital of La Réunion, after authorization from the “Commission de Déontologie de la Fonction Publique” was obtained. Dr B. Gouyon remained closely involved in the research project issued from the B-PEN database particularly in setting of the data warehouse, treatment of data and writing of this manuscript. Pr J-B. Gouyon (the corresponding author) has no function, no shares, no role, nor any financial relationship in and with the LogipremF company. Additionally, he has no other competing interests. As a corresponding author and to the best of my knowledge, other authors have no potential conflicts of interest. This does not alter our adherence to all PLOS ONE policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF
6. Assessment of policy and access to HIV prevention, care, and treatment services for men who have sex with men and for sex workers in Burkina Faso and Togo.
- Author
-
Duvall S, Irani L, Compaoré C, Sanon P, Bassonon D, Anato S, Agounke J, Hodo A, Kugbe Y, Chaold G, Nigobora B, and MacInnis R
- Subjects
- Burkina Faso epidemiology, Female, HIV Infections epidemiology, Humans, Male, Prevalence, Rape, Togo epidemiology, HIV Infections prevention & control, Health Policy, Health Services Accessibility statistics & numerical data, Homosexuality, Male, Sex Workers
- Abstract
Background: In Burkina Faso and Togo, key populations of men who have sex with men (MSM) and sex workers (SW) have a disproportionately higher HIV prevalence. This study analyzed the 2 countries' policies impacting MSM and SW; to what extent the policies and programs have been implemented; and the role of the enabling environment, country leadership, and donor support., Methods: The Health Policy Project's Policy Assessment and Advocacy Decision Model methodology was used to analyze policy and program documents related to key populations, conduct key informant interviews, and hold stakeholder meetings to validate the findings., Results: Several policy barriers restrict MSM/SW from accessing services. Laws criminalizing MSM/SW, particularly anti-solicitation laws, result in harassment and arrests of even nonsoliciting MSM/SW. Policy gaps exist, including few MSM/SW-supportive policies and HIV prevention measures, e.g., lubricant not included in the essential medicines list. The needs of key populations are generally not met due to policy gaps around MSM/SW participation in decision-making and funding allocation for MSM/SW-specific programming. Misaligned policies, eg, contradictory informed consent laws and protocols, and uneven policy implementation, such as stockouts of sexually transmitted infection kits, HIV testing materials, and antiretrovirals, undermine evidence-based policies. Even in the presence of a supportive donor and political community, public stigma and discrimination (S&D) create a hostile enabling environment., Conclusions: Policies are needed to address S&D, particularly health care provider and law enforcement training, and to authorize, fund, guide, and monitor services for key populations. MSM/SW participation and development of operational guidelines can improve policy implementation and service uptake.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.